Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025 (Katherine Davis/Axios)

Pathos AI, a precision oncology biotech using AI to develop drugs, raised $237 million in a Series E round at a $3 billion post-money valuation, up from $1.6 billion in May 2025.